The Ministry of Health, Labour and Welfare Japan has approved Kisunlatm (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's Alzheimer's treatment for ...
Some results have been hidden because they may be inaccessible to you